Navigation Links
Schuco® 3000 Nebulizer

ProductsSchuco® 3000 Nebulizer
Company Allied Healthcare Products, Inc.
Item Schuco® 3000 Nebulizer
Features 
  • Completely self-enclosed for ease of cleaning
  • 5-year warranty
  • Easily portable
  • New lighweight, compact design
  • Quiet
  • Trusted Schuco engineering for reliable performance at an affordable price
  • Recessed tubing connector
  • Damage-resistant plastic
  • Convenient cord storage
  • UL listed
  • Made in the USA
Description Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy.
Info Allied Healthcare Products, Inc.
Customer Service: (800) 444-3940
Web site: http://www.alliedhpi.com/

Related medicine products :

1. DeVilbiss Pulmo-Aide® Compact Compressor/Nebulizer With Reusable Neb
2. DeVilbiss Pulmo-Aide® Compact Compressor/Nebulizer With Disposable Neb
3. TransNeb™ Compact Compressor/Nebulizer System
4. SportNeb™ Ultra Light Nebulizer/Compressor
5. SuperSportNeb™ Nebulizer Compressor
6. AeroMax™ The Ultimate Nebulizer/Compressor
7. Portable Compressor Nebulizer
8. CompAir Elite Compressor Nebulizer System
9. Nebulite™ LT2 Nebulizer Compressor
10. CompAir XLT Compressor Nebulizer System
11. CompAir® XL Compressor Nebulizer System
The inventory system designed for Wholesale Distributors and centralized distribution centers for Optical chains.
...Ordering/Dispensing has gained recognition as the ... lens ordering system. It enables opticians to pla...g SDS electronic communications technology. When u...r 3D frame tracers, lens shapes are automatically ...
... is a complete practice and business management so...ts, opticians and ophthalmologists- It is designed...ally rich and intuitive windows interface with a f...- The multi-user version of this practice and Busi...
The K-4500 automated hematology analyzer offers fast reliable test results of 18-parameter plus 3-histograms, valuable for effective diagnosis.
Medicine Products:
(Date:12/2/2008)...image-guided treatment is a safe and precise metho...om the body, according to the first report on "sel...licted foreign body insertion in adolescents. The ...ting of the Radiological Society of North America ... to be the first to detect self-embedding disorder...
(Date:12/2/2008)...ewswire/ -- Research scientists using a,novel, ha...I) have found that,chronic stroke patients can be...day at the annual meeting of the Radiological Soci...udy using fMRI to map the brain in order to track,...at the brain has the ability to regain function th...
(Date:12/2/2008)...c. 1 diaDexus, Inc. today,announc...ated format of the,PLAC Test for Lp-PLA2. This au...nning on a wide range of clinical chemistry analyz... Administration (FDA) in December 2007. diaDexus a... PLAC Test to Europe. , The PLAC Test is th...
(Date:12/2/2008)...re/ -- At a symposium today hosted by Johns,Hopk...nce researchers presented,the latest research in ...g the,science into technology to improve lives. H...sented evidence that cognitive intervention develo...ty, the brain,s ability to,reorganize itself thro...
Breaking Medicine News(10 mins):Health News:Radiologists diagnose and treat self-embedding disorder in teens 2Health News:Robotic Technology Improves Stroke Rehabilitation 2Health News:Robotic Technology Improves Stroke Rehabilitation 3Health News:diaDexus Receives CE Mark Certification for the PLAC(R) Test 2Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2
...ssociation between the level of sex hormones and a...eptors for the female hormones estrogen and proges...eptors are the eyes and ears of the cells, receivi... hormones. Estrogen and progesterone stimulate gro...
...acupuncture can help those suffering from arthriti...rrent multi-location trial included 570 patients a...articipants were placed in three groups. One hundr...ure, 191 underwent sham acupuncture, and 189 follo...
...ns are currently performed among the diabetic popu... blood vessels in the retinas of about 900 diabeti... before age 30. All were followed for 20 years to ...ight relate to subsequent need for an amputation. ...
... of countries where iodine deficiency is a public ... on a new global report on iodine status.// The si...ed well. The number of countries where iodine defi...reduced to 54 in 2003, from 110 in 1993. "Iodine d...
Other Medicine News:Health News:WHO hopes to wipe away Iodine deficiency diseases by 2005 2
(Date:12/2/2008)...ll., Dec. 2 Horizon Therapeutics, ... today announced that two pivotal,Phase 3 trials ...ate, HZT-501,met all primary endpoints. HZT-501,...uct containing ibuprofen and famotidine, demonstra...incidence of non-steroidal,anti-inflammatory drug...
(Date:12/1/2008)..., Dec. 1 TargeGen has announced th...rom a multi-center, US-based clinical,trial of TG...been scheduled at,the 2008 American Society of He...presentation are as follows:, Title: ...ailable, JAK2-Selective In...
(Date:12/1/2008)...tinence is still the best policy , , ROCHE...ew study from Mayo Clinic finds the use of the dru...olic hepatitis, an acute inflammation of the liver...esults of the study are published in the December ...rnal.org/ ). , , VIDEO ALERT: Additional a...
(Date:12/1/2008)..., Dec. 1 Vical Incorpora...of a $1.0 million milestone payment from Merck &am...f a Phase I clinical trial of an investigational p...ccine is based on Vical,s DNA gene delivery techno...ptase (hTERT). hTERT is the subject of separate li...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 1Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 2Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 3Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 4Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 5Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 6Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 7Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 8Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 9Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 10Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference 7705 1Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference 7705 2Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 1Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 2Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 3Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 1Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 2Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 3Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 4Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 5Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 6Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 7Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 8Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 9Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 10Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 11Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 12Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 13Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 14
... the Journal of Clinical Oncology -, NEW YORK, Jul...a,Phase II study - which will be published in the ...ncology (JCO) and are now,available as an Early Re...www.jco.org/">www.jco.org - demonstrate that,ixab...ional,compound, has activity in patients with meta...
... TMC125, an Investigational NNRTI,from Tibotec, YA...m two,ongoing Phase 3 studies (DUET-1 and DUET-2) ...h documented non-nucleoside reverse,transcriptase ...stance reached an undetectable viral load (defined...V-1 RNA copies/mL) with,TMC125 (etravirine), Tibot...
Other Medicine Technology:Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 2Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 3Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,and Capecitabine 4TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4